DOUGLAS W. BLAYNEY, M.D.; ELAINE S. JAFFE, M.D.; RICHARD I. FISHER, M.D.; GERALDINE P. SCHECHTER, M.D.; JEFFREY COSSMAN, M.D.; MARJORIE ROBERT-GUROFF, Ph.D.; V. S. KALYANARAMAN, Ph.D.; WILLIAM A. BLATTNER, M.D.; ROBERT C. GALLO, M.D.
▸Requests for reprints should be addressed to Douglas W. Blayney, M.D.; Landow Building, Room 4C18, National Institutes of Health; Bethesda, MD 20205.
BLAYNEY D., JAFFE E., FISHER R., SCHECHTER G., COSSMAN J., ROBERT-GUROFF M., KALYANARAMAN V., BLATTNER W., GALLO R.; The Human T-cell Leukemia/Lymphoma Virus, Lymphoma, Lytic Bone Lesions, and Hypercalcemia. Ann Intern Med. 1983;98:144-151. doi: 10.7326/0003-4819-98-2-144
Download citation file:
Published: Ann Intern Med. 1983;98(2):144-151.
The human T-cell lymphoma (HTL) virus is a type C RNA tumor virus isolated from patients with malignancies of mature T cells. We report three patients with peripheral T-cell lymphoma, hypercalcemia, and antibodies to HTL virus. One patient presented with idiopathic hypercalcemia of 6 months' duration, two with striking lytic bone lesions, and two with circulating malignant lymphocytes. Malignant cells from all patients had surface markers characteristic of thymic-derived lymphocytes (T cells), and all patients had natural serum antibodies to disrupted HTL virus and to one or both viral structural proteins p19 and p24. Patients with adult peripheral T-cell lymphomas, particularly those that present with hypercalcemia and lytic bone lesions, may have antibodies to the type C RNA human tumor virus, HTL virus.
to gain full access to the content and tools.
Learn more about subscription options.
Register Now for a free account.
Endocrine and Metabolism, Hematology/Oncology, Nephrology, Fluid and Electrolyte Disorders, Leukemia/Lymphoma.
Results provided by:
Copyright © 2016 American College of Physicians. All Rights Reserved.
Print ISSN: 0003-4819 | Online ISSN: 1539-3704
Conditions of Use
This PDF is available to Subscribers Only